ClinicalTrials.gg

Program

enarodustat

Also written as “JTZ-951”, “Enarodustat 2mg” and “Enarodustat 3mg”.

Its studies are mostly in Anemia · Kidney Failure, Chronic, led by 3 companies.

Furthest: phase 4, since Oct 15, 20136 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi40 open or runningphase 1since Oct 15, 2013Oct 15, 2013none ahead
JW Pharmaceutical10 open or runningphase 3since Jul 10, 2019Jul 10, 2019none ahead
Shenzhen Salubris Pharmaceuticals11 open or runningphase 4since Jul 6, 2025Jul 6, 2025Jun 2027phase 4 · NCT07079579

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2013First study: phase 1 study in AnemiaNew to ShionogiShionogi · NCT01971164 · 29 enrolled · United States
  2. Nov 1, 2013Phase 1 study in Kidney Failure, ChronicShionogi · NCT01978587 · 6 enrolled · United States
  3. Oct 19, 2015Phase 1 study in Anemia of Chronic Kidney DiseaseShionogi · NCT02581124 · 10 enrolled · United States
  4. Jun 15, 2016Phase 1 study in Anemia of Chronic Kidney DiseaseShionogi · NCT02805244 · 6 enrolled · United States
  5. Jul 10, 2019JW Pharmaceutical's first study: phase 3 study in Anemia of Chronic Kidney DiseaseNew to JW PharmaceuticalJW Pharmaceutical · NCT04027517 · 172 enrolled · Korea, Republic of
  6. Jul 6, 2025Shenzhen Salubris Pharmaceuticals's first study: phase 4 study in Renal Anemia in Non-dialysis Chronic Kidney DiseaseNew to Shenzhen Salubris PharmaceuticalsShenzhen Salubris Pharmaceuticals · NCT07079579 · 120 planned · China

Ahead

  1. Jun 2027Primary completion: phase 4 study in Renal Anemia in Non-dialysis Chronic Kidney DiseaseShenzhen Salubris Pharmaceuticals · NCT07079579

TargetBeta

EGLN1 →read by rule
“Egl nine homolog 1 inhibitor”ChEMBL 37, by rule

Other programs on EGLN1

ProgramCompanyFurthest phaseStudies
roxadustatruleAstellas Pharmaphase 447
vadadustatruleAkebia Therapeuticsphase 336
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07079579Renal Anemia in Non-dialysis Chronic Kidney Disease · China4Not yet recruitingShenzhen Salubris PharmaceuticalsJun 2027120
NCT04027517Anemia of Chronic Kidney Disease · Korea, Republic of3CompletedJW PharmaceuticalFeb 23, 2021172
NCT02805244Anemia of Chronic Kidney Disease · United States1CompletedShionogiSep 20166
NCT02581124Anemia of Chronic Kidney Disease · United States1CompletedShionogiApr 201610
NCT01978587Kidney Failure, Chronic · United States1CompletedShionogiDec 20136
NCT01971164Anemia · United States1CompletedShionogiMay 201429

How it is read

Names in the registry

  • “JTZ-951”, 4 entries
  • “Enarodustat 2mg”, 1 entry
  • “Enarodustat 3mg”, 1 entry
  • “Enarodustat 4mg”, 1 entry
  • “JTZ-951, 14C-JTZ-951”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.